SCHEMBL141601

SCHEMBL141601

CC(=O)c1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.86
DRD2 P14416 7/20 0.86
SLC6A2 P23975 7/20 0.86
SLC6A4 P31645 7/20 0.86
ADRA1A P35348 7/20 0.86
DRD3 P35462 7/20 0.86
SLC6A3 Q01959 7/20 0.86
KCNH2 Q12809 7/20 0.86
HRH1 P35367 7/20 0.86
ADRA2C P18825 6/20 0.86
HTR2A P28223 6/20 0.86
ADRA2A P08913 6/20 0.86
DRD1 P21728 6/20 0.86
ADRA2B P18089 5/20 0.86
HTR2B P41595 4/20 0.86
HRH3 Q9Y5N1 4/20 0.86
MLNR O43193 2/20 0.86
ESR1 P03372 2/20 0.86
PTGS2 P35354 1/20 0.86
CHRM1 P11229 6/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetophenazine SCHEMBL29710923 0.92 HRH1 (1.00) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Acetophenazine SCHEMBL94266 0.92 HRH1 (1.00) HTR1ADRD2SLC6A2SLC6A4ADRA1A
SCHEMBL26837052 0.89 HRH1 (0.69) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Acetophenazine SCHEMBL27848793 0.89 HRH1 (0.89) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Acetophenazine SCHEMBL28843774 0.88 HTR1A (0.79) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Butaperazine SCHEMBL29710903 0.87 HRH1 (0.67) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Butaperazine SCHEMBL28086241 0.87 HRH1 (0.67) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Butaperazine SCHEMBL31153317 0.87 HRH1 (0.67) HTR1ADRD2SLC6A2SLC6A4ADRA1A
Butaperazine SCHEMBL119995 0.87 HRH1 (0.67) HTR1ADRD2SLC6A2SLC6A4ADRA1A
SCHEMBL24220374 0.87 HRH1 (0.66) HTR1ADRD2SLC6A2SLC6A4ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130204238-A1 COMBINATION THERAPY FOLLICA, INC (US) 2013-08-08 US disclosed
EP-2552323-A1 COMBINATION THERAPY Follica, Inc. (US) 2013-02-06 EP disclosed
US-8252749-B2 Methods, kits, and compositions for generating new hair follicles and growing hair FOLLICA, INC. (US) 2012-08-28 US disclosed
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair FOLLICA, INC. (US) 2012-06-21 US disclosed
WO-2012067631-A1 BODY SURFACE TREATMENT FOLLICA, INC. (US) 2012-05-24 WO disclosed
WO-2012067632-A1 SEQUENTIAL BODY SURFACE TREATMENT FOLLICA, INC. (US) 2012-05-24 WO disclosed
WO-2012067630-A1 HAIR GROWTH TREATMENT FOLLICA, INC. (US) 2012-05-24 WO disclosed
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS ZALICUS INC. (US) 2012-03-08 US disclosed
US-8080553-B2 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. (US) 2011-12-20 US disclosed
WO-2011123218-A1 COMBINATION THERAPY FOLLICA, INC. (US) 2011-10-06 WO disclosed
EP-1599212-A4 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2006-02-08 EP disclosed
EP-1599212-A2 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS Combinatorx, Incorporated (US) 2005-11-30 EP disclosed
US-20050192261-A1 Methods and reagents for the treatment of immunoinflammatory disorders COMBINATORX INCORPORATED 2005-09-01 US disclosed
US-20050119160-A1 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. 2005-06-02 US disclosed
US-20050112199-A1 Therapeutic regimens for administering drug combinations COMBINATORX, INCORPORATED 2005-05-26 US disclosed
WO-2005037203-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-04-28 WO disclosed
WO-2005030132-A2 THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2005-04-07 WO disclosed
WO-2005027839-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-03-31 WO disclosed
US-20040224876-A1 Combination therapy for the treatment of immunoinflammatory disorders COMBINATORX, INCORPORATED 2004-11-11 US disclosed
WO-2004073614-A2 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192261-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, CMA1, CCL11 HTR1A 615/4885DRD2 2151/4885SLC6A2 1883/4885
US-20040224876-A1 Combination therapy for the treatment of immunoinflammatory disorders HLA-DRB1, TSLP, SERPINA6 HTR1A 2037/4885DRD2 3053/4885SLC6A2 1019/4885
US-20120156228-A1 Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair NGF, HDGF, SHH HTR1A 3138/4885DRD2 4463/4885SLC6A2 4668/4885
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS IL5, TPMT, TSLP HTR1A 3556/4885DRD2 4506/4885SLC6A2 3188/4885
US-20050119160-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, TPMT, TSLP HTR1A 3556/4885DRD2 4506/4885SLC6A2 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.